Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors.
The emergence of immune checkpoint inhibitors (ICIs), mainly based on PD-1/PD-L1 blockade has revolutionized the therapeutic landscape of cancer. Despite the huge clinical success ICIs have achieved, about 70% of patients still showed de novo and adaptive resistance. Exploring novel and complementar...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2021-01-01
|
| coleção: | Cancer Treatment and Research Communications |
| Assuntos: | |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S2468294221001635 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|